k Anitviral Molnupiravir interfering SARSCoV2 replication Illustration of antiviral drug Molnupiravir ball and stick model incorporating itself into a SARSCoV2 RNA ribonucleic acid, yellow strand. Molnupiravir is a nucleoside analogue of cytidine and uridine. The drug is inserted into the RNA strand instead of cytidine or uridine. The coronaviruss proofreading enzymes, which check for mutations in the RNA strand, do not recognise that Molnupiravir has been inserted instead. This causes RNA polymerase to make copies of the faulty RNA strand, which encodes for nonfunctional proteins. Molnupiravir has been approved for use in the UK for patients with moderate to mild Covid19 with other risk factors such obesity, obesity, older age and diabetes mellitus., Photo by RAMON ANDRADE 3DCIENCIASCIENCE PHOTO LIBRARY Stock Photo - Afloimages
Sign up
Login
All images
Anitviral Molnupiravir interfering SARS CoV 2 replication Illustration of antiviral drug Molnupiravir  ball and stick model  incorporating itself into a SARS CoV 2 RNA  ribonucleic acid, yellow  strand. Molnupiravir is a nucleoside analogue of cytidine and uridine. The drug is inserted into the RNA strand instead of cytidine or uridine. The coronavirus s proofreading enzymes, which check for mutations in the RNA strand, do not recognise that Molnupiravir has been inserted instead. This causes RNA polymerase to make copies of the faulty RNA strand, which encodes for non functional proteins. Molnupiravir has been approved for use in the UK for patients with moderate to mild Covid 19 with other risk factors such obesity, obesity, older age and diabetes mellitus., Photo by RAMON ANDRADE 3DCIENCIA SCIENCE PHOTO LIBRARY
RM

Anitviral Molnupiravir interfering SARS-CoV-2 replication

Illustration of antiviral drug Molnupiravir (ball and stick model) incorporating itself into a SARS-CoV-2 RNA (ribonucleic acid, yellow) strand. Molnupiravir is a nucleoside analogue of cytidine and uridine. The drug is inserted into the RNA strand instead of cytidine or uridine. The coronavirus's proofreading enzymes, which check for mutations in the RNA strand, do not recognise that Molnupiravir has been inserted instead. This causes RNA polymerase to make copies of the faulty RNA strand, which encodes for non-functional proteins. Molnupiravir has been approved for use in the UK for patients with moderate to mild Covid-19 with other risk factors such obesity, obesity, older age and diabetes mellitus., Photo by RAMON ANDRADE 3DCIENCIA/SCIENCE PHOTO LIBRARY

Details

ID
180851445

Collection

License type
Rights Managed

Photographer



Sign in
Member access
Login not found.